已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Endoscopic Endonasal Surgery Treatment Strategies for Invasive Pituitary Adenoma: Analysis of Four Approaches

医学 外科 垂体腺瘤 神经外科 鼻内镜手术 垂体机能减退 治愈率 内窥镜检查 阶段(地层学) 腺瘤 内科学 颅骨 生物 古生物学
作者
Yang Ji-Hu,Huang Guo-dong,Ji Tao,Wang Hai-Dong,Liu Yu-fei,Guo Jian,Li Zhen,Li Wei-Ping
出处
期刊:World Neurosurgery [Elsevier]
被引量:8
标识
DOI:10.1016/j.wneu.2018.02.162
摘要

To explore the surgical methods and clinical effect of endoscopic endonasal approaches for the treatment of invasive pituitary adenomas (IPAs).A retrospective analysis was made of the clinical data of 74 patients (75 procedures) with IPAs treated by different endoscopic endonasal approaches at the Department of Neurosurgery, The First Affiliated Hospital of Shenzhen University from May 2014 to August 2017. The data include clinical manifestation, imaging features, surgical methods and complications, resection rate, cure rate, prognosis, and complications in different Knosp classifications and Hardy stages. The transcavernous approach was used in 47 patients, the lateral-cavernous approach was used in 14 patients, the tuberculum sella planum approach was used in 8 patients, and the diaphragma sellae open or dorsum sellae cut approach was used in 6 patients.The gross total resection (GTR) rate was 70.7% (53 patients) and tumor residue rate was 29.3% (22 patients). GTR rate for pituitary adenoma according to Knosp classification was 89.3% in grade 3 and 28.6% in grade 4. The biology cure rate was 75.0% and 23.8%, respectively. There was significance between them (P < 0.05). In addition, the GTR rate of Hardy stage was 90.5% in stage C, 90.0% in stage D, 26.1% in stage E, and the biology cure rate was 80.1%, 75.0%, and 13.0%, respectively. There was significance among them (P < 0.05) Postoperative severe complications included 9 patients (12.0%) with cerebrospinal fluid leaks, 26 patients (34.7%)with electrolyte imbalance, 36 patients (48.0%) with transient diabetes insipidus, 22 patients (29.3%) with hypopituitarism, 2 patients (2.7%) with permanent hypopituitarism, and 2 patients (2.7%)with epistaxis. The follow-up lasted 2-41 months (average, 19.3 months). No patient experienced recurrence after GTR, 1 patient undergoing subtotal experienced recurrence and underwent reoperation, 3 patients underwent postoperative Gamma Knife treatment, and 2 patients with refractory IPA were given temozolomide and metformin chemotherapy.According to the invasiveness of IPA, choosing the appropriate endoscopic surgical approach is helpful in removing tumors and reducing complications.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ajun完成签到,获得积分10
刚刚
刚刚
刚刚
1秒前
聪明的黑猫完成签到 ,获得积分10
1秒前
gtgyh完成签到 ,获得积分10
2秒前
好好好发布了新的文献求助10
3秒前
Ethan完成签到 ,获得积分10
3秒前
lameliu发布了新的文献求助10
4秒前
5秒前
团子好无情完成签到 ,获得积分10
5秒前
科研66666完成签到 ,获得积分10
5秒前
万能图书馆应助Yxs采纳,获得10
8秒前
lili完成签到 ,获得积分10
8秒前
蔷薇完成签到 ,获得积分10
10秒前
困困完成签到 ,获得积分10
11秒前
哇哇哇完成签到 ,获得积分10
13秒前
搜集达人应助lbw采纳,获得10
13秒前
阳光的衫完成签到,获得积分10
14秒前
体贴琳完成签到 ,获得积分10
14秒前
星辰大海应助666采纳,获得10
17秒前
影1发布了新的文献求助10
17秒前
欢呼宛秋完成签到,获得积分10
19秒前
19秒前
20秒前
Suraim完成签到,获得积分10
20秒前
情怀应助好好好采纳,获得10
21秒前
坚守完成签到 ,获得积分10
22秒前
白沙湾完成签到,获得积分10
23秒前
大门神发布了新的文献求助10
25秒前
沈澜完成签到 ,获得积分10
26秒前
一榔头发布了新的文献求助10
27秒前
田様应助一榔头采纳,获得20
32秒前
33秒前
李健应助momo采纳,获得10
34秒前
weirdog给weirdog的求助进行了留言
34秒前
斯文败类应助何茂郎采纳,获得10
34秒前
魔幻冰棍完成签到 ,获得积分10
34秒前
懵懂的小夏完成签到,获得积分10
35秒前
wl完成签到 ,获得积分10
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Binary Alloy Phase Diagrams, 2nd Edition 8000
Building Quantum Computers 800
Translanguaging in Action in English-Medium Classrooms: A Resource Book for Teachers 700
Natural Product Extraction: Principles and Applications 500
Exosomes Pipeline Insight, 2025 500
Red Book: 2024–2027 Report of the Committee on Infectious Diseases 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5663937
求助须知:如何正确求助?哪些是违规求助? 4854696
关于积分的说明 15106497
捐赠科研通 4822285
什么是DOI,文献DOI怎么找? 2581341
邀请新用户注册赠送积分活动 1535521
关于科研通互助平台的介绍 1493759